Non-Muscle Invasive Bladder Cancer Treatment
Aug 30, 2024
NMIBC Treatment Paradigm Evolution: A Look At The Clinical Development Shift From High-Risk Bcg Unresponsive To Untapped High-Risk Bcg Naïve And Intermediate-Risk NMIBC
A high cure rate characterizes Non-muscle Invasive Bladder Cancer (NMIBC), yet there is a notable risk of recurrence and progression to muscle-invasive disease. Effective NMIBC management involves precise local resection, staging, and a risk-based approach with intravesical agents. The conventional gold standard fo...
Read More...
Aug 26, 2024
Imbalance Between BCG Supply and Increased Demand: The Crisis Impacting Bladder Cancer Treatment
The BCG vaccine, a significant medical breakthrough developed in the early 20th century, is derived from a strain of Mycobacterium bovis initially created by the University of Illinois as a vaccine against tuberculosis. For NMIBC, BCG is administered intravesically to reduce the risk of cancer recurrence and progre...
Read More...
Apr 01, 2024
Advances in Non-Muscle Invasive Bladder Cancer Treatment: Exploring Emerging Therapies
Non-muscle-invasive bladder cancer represents a category of bladder cancer where the tumor is confined to the innermost layer of the bladder lining without invading the muscle. This early-stage form accounts for a significant proportion of bladder cancer cases. Among the 7MM, the US accounted for the highest num...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
